Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
March 30th, 2020
7.6K views
Presented here is a protocol for the use of alginate as a polymer in microencapsulation of immortalized cells for long-term delivery of biologics to rodent eyes.
Overview
This protocol outlines the use of alginate as a polymer for microencapsulation of immortalized cells, facilitating long-term delivery of biologics to rodent eyes. This method allows for targeted delivery of therapeutic agents while minimizing immune reactions.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- Ocular Therapeutics
Background
- Microencapsulation techniques are essential for localized delivery of therapeutics.
- Alginate is a biocompatible polymer suitable for cell encapsulation.
- This method can be applied to various diseases, including ocular conditions.
- Maintaining a sustained release of therapeutics is crucial for effective treatment.
Purpose of Study
- To develop a reliable method for delivering biologics to specific sites in rodent eyes.
- To enhance the therapeutic efficacy of encapsulated cells.
- To minimize immune responses associated with cell delivery.
Methods Used
- Culturing retinal epithelial cells according to established protocols.
- Passaging cells at 70-80% confluency using standard tissue culture techniques.
- Utilizing alginate microcapsules for cell encapsulation.
- Monitoring the release and delivery of therapeutics over time.
Main Results
- Successful encapsulation of retinal epithelial cells in alginate microcapsules.
- Demonstrated sustained release of therapeutic agents.
- Minimal immune reaction observed in rodent models.
- Potential applications in treating ocular and other diseases.
Conclusions
- Alginate microencapsulation is a promising method for targeted delivery of therapeutics.
- This technique can enhance treatment outcomes for various diseases.
- Further studies are needed to optimize the delivery system.
Frequently Asked Questions
What is alginate used for in this study?
Alginate is used as a polymer for microencapsulation of cells to deliver biologics to rodent eyes.
How does this method minimize immune reactions?
The use of alginate microcapsules allows for targeted delivery without triggering significant immune responses.
What types of diseases can this method potentially treat?
This method can be applied to treat ocular diseases as well as other conditions such as cardiac diseases.
What are the advantages of using microencapsulation?
Microencapsulation allows for sustained release of therapeutics and targeted delivery to specific sites.
What is the significance of culturing retinal epithelial cells?
Culturing these cells is essential for creating a reliable source for encapsulation and therapeutic delivery.
How can the release of therapeutics be monitored?
The release can be tracked through various experimental techniques that measure the concentration of therapeutics over time.
Executive Industry Relevance
Encapsulated cell technology enables sustained local delivery of biologics to the posterior eye, reducing dosing frequency and immune activation. This approach supports preclinical evaluation of long-acting protein therapeutics in ocular disease models. It provides a translatable platform for de-risking biologic delivery strategies prior to IND-enabling studies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables functional validation of secreted biologics in vivo through controlled, long-term release.
- Operational Value: Provides a reusable system for testing therapeutic protein efficacy without repeated dosing.
Screening & Assay Development
- Scientific Value: Generates quantifiable, sustained biomarker readouts from encapsulated cell implants.
- Operational Value: Standardizes microcapsule size and viability for reproducible ocular delivery.
Translational & Preclinical Research
- Scientific Value: Supports dose-response modeling via tunable release kinetics in disease-relevant ocular models.
- Operational Value: Allows longitudinal monitoring of therapeutic effect and tissue response.
Pipeline & Workflow Integration
This method bridges early discovery and preclinical validation by providing a stable delivery system for biologic candidates in ocular disease models.
- Discovery Biology: Tests hypothesis of target engagement through sustained local biologic presence.
- Screening: Delivers consistent biologic exposure for evaluating lead candidates in vivo.
- Analytics: Enables measurement of vitreous biomarker levels over time to assess release profiles.
- Translational Research: Connects in vitro encapsulation efficacy to in vivo ocular distribution and persistence.
- Enterprise Reuse: Encapsulation process can be adapted across cell lines and biologics for platform-wide application.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity by maintaining stable biologic concentrations in target tissue.
- Operational Value: Eliminates need for frequent intravitreal injections, improving study throughput.
- Strategic Value: Increases predictive confidence in biologic half-life and tissue retention.
- Portfolio Impact: Informs go/no-go decisions based on durable target modulation in disease models.
Implementation Considerations
- Cell culture expertise for maintaining ARPE-19 viability and functionality.
- Electrospray equipment and high-voltage control for consistent microcapsule formation.
- Sterile technique and ocular microsurgery training for intravitreal delivery.
- Viability and size validation via LIVE/DEAD assay and brightfield imaging.
- Avoidance of PBS in washing steps to prevent alginate dissolution.
Biopharma FAQs
Why does encapsulation prevent immune rejection of delivered cells?
The alginate membrane acts as a semi-permeable barrier that allows nutrient and therapeutic exchange while shielding encapsulated cells from host immune components, thereby avoiding the need for immunosuppression.
How does electrospray contribute to uniform microcapsule production?
Electrospray uses voltage and flow rate control to generate monodisperse alginate droplets that gel upon contact with calcium bath, yielding microcapsules of approximately 150 micrometers in size for consistent ocular delivery.
What measurements confirm successful cell encapsulation and viability?
Brightfield imaging confirms microcapsule integrity and size, while LIVE/DEAD assay staining demonstrates approximately 90% cell viability post-encapsulation, indicating preserved cellular function within the hydrogel matrix.
Why is replication important for validating ocular delivery consistency?
Replication across multiple animals ensures reproducible capsule distribution in the vitreous and reliable therapeutic readouts, supporting cross-functional agreement on delivery efficacy and enabling standardized preclinical evaluation.
What statistical analysis is needed to assess sustained release from encapsulated cells?
Longitudinal sampling of vitreous humor or tear fluid requires repeated measures analysis or non-linear regression to model therapeutic concentration over time, enabling comparison of release kinetics between formulations or cell lines.
